Recurrence monitoring of colorectal and breast cancer patients with egSEQ Comprehensive Solid Tumour

With the continuous discovery of genetic targets correlated with recurrence risk, time to recurrence (TTC) and/or overall survival, it is important for patients and clinicians to identify cases that would benefit from extended treatment and lower the chances of cancer recurrence (Smolle et al., 2015).

The recurrence of early-stage colorectal cancer is found to be low (~12%), while the overall colorectal disease recurrence and the possibility of developing distal metastases are closer to 50% (Kim et al., 2019). Breast cancer recurrence rates are also generally low, with most cases occurring in the 5-year after diagnosis, with the exception that the women with ER-positive breast cancer remain at a 2% annual rate for at least 15 years after the primary tumour has been treated (Sestak et al, 2015).

Table 1. Examples of genes that may facilitate cancer recurrence in patients.

Combined with the latest research, our egSEQ library preparation and targeted sequencing solutions are utilised for cancer screening and genomic profiling to provide individual patients with an opportunity for optimal treatment depending on the aspect of their cancer type. egSEQ Comprehensive Solid Tumours Panel incorporates 641 genes, with a special focus on known MSI and fusion regions, and can be used at every step of the cancer diagnostics process.

Related Links:

  1. egSEQ Comprehensive Solid Tumours

  2. egSEQ Whole Exome

  3. Library Preparation

  4. Access to genetic testing and the role of effective genetic counselling


1. Kim, S. K., Kim, S. Y., Kim, C. W., Roh, S., Ha, Y. J., Lee, J. L., ... & Kim, J. C. (2019). A prognostic index based on an eleven gene signature to predict systemic recurrences in colorectal cancer. Experimental & molecular medicine, 51(10), 1-12.

2. Liu, M. C., Dixon, J. M., Xuan, J. J., Riggins, R. B., Chen, L., Wang, C., ... & Clarke, R. (2011). S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen. Cancer Research, 71(24_Supplement), S1-8.

3. Sestak, I., & Cuzick, J. (2015). Markers for the identification of late breast cancer recurrence. Breast Cancer Research, 17(1), 1-8.

4. Smolle, M. A., Pichler, M., Haybaeck, J., & Gerger, A. (2015). Genetic markers of recurrence in colorectal cancer. Pharmacogenomics, 16(11), 1313-1326.

5. Zhai, X., Xue, Q., Liu, Q., Guo, Y., & Chen, Z. (2017). Colon cancer recurrence‑associated genes revealed by WGCNA co‑expression network analysis. Molecular Medicine Reports, 16(5), 6499-6505.

#Oncology #ComprehensiveSolidTumours